Proteome-based classification of Nonmuscle Invasive Bladder Cancer

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3077713 67 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Proteome-based classification of Nonmuscle Invasive Bladder Cancer
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
DNA/RNA-based classification of bladder cancer (BC) supports the existence of multiple molecular subtypes, while investigations at the protein level are scarce. Here, we aimed to investigate if Nonmuscle Invasive Bladder Cancer (NMIBC) can be stratified to biologically meaningful groups based on the proteome. Tissue specimens from 117 patients at primary diagnosis (98 with NMIBC and 19 with MIBC), were processed for high-resolution proteomics analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The proteomics output was subjected to unsupervised consensus clustering, principal component analysis (PCA) and investigation of subtype-specific features, pathways, and gene sets. NMIBC patients were optimally stratified to three NMIBC proteomic subtypes (NPS), differing in size, clinicopathologic and molecular backgrounds: NPS1 (mostly high stage/grade/risk samples) was the smallest in size (17/98) and overexpressed proteins reflective of an immune/inflammatory phenotype, involved in cell proliferation, unfolded protein response and DNA damage response, whereas NPS2 (mixed stage/grade/risk composition) presented with an infiltrated/mesenchymal profile. NPS3 was rich in luminal/differentiation markers, in line with its pathological composition (mostly low stage/grade/risk samples). PCA revealed a close proximity of NPS1 and conversely, remoteness of NPS3 to the proteome of MIBC. Proteins distinguishing these two extreme subtypes were also found to consistently differ at the mRNA levels between high and low-risk subtypes of the UROMOL and LUND cohorts. Collectively, our study identifies three proteomic NMIBC subtypes and following a cross-omics validation in two independent cohorts, shortlists molecular features meriting further investigation for their biomarker or potentially therapeutic value. © 2019 UICC
Έτος δημοσίευσης:
2020
Συγγραφείς:
Stroggilos, R.
Mokou, M.
Latosinska, A.
Makridakis, M.
Lygirou, V.
Mavrogeorgis, E.
Drekolias, D.
Frantzi, M.
Mullen, W.
Fragkoulis, C.
Stasinopoulos, K.
Papadopoulos, G.
Stathouros, G.
Lazaris, A.C.
Makrythanasis, P.
Ntoumas, K.
Mischak, H.
Zoidakis, J.
Vlahou, A.
Περιοδικό:
International Journal of Cancer
Εκδότης:
Wiley-Liss, Inc.
Τόμος:
146
Αριθμός / τεύχος:
1
Σελίδες:
281-294
Λέξεις-κλειδιά:
messenger RNA; proteome; messenger RNA; proteome; tumor marker, aged; Article; cancer classification; cancer diagnosis; cancer grading; cancer risk; cancer staging; cell proliferation; cohort analysis; DNA damage response; female; human; human tissue; liquid chromatography-mass spectrometry; major clinical study; male; muscle invasive bladder cancer; non muscle invasive bladder cancer; phenotype; priority journal; protein expression; proteomics; tumor volume; unfolded protein response; bladder tumor; disease exacerbation; inflammation; Kaplan Meier method; liquid chromatography; metabolism; pathology; procedures; prognosis; tandem mass spectrometry, Aged; Biomarkers, Tumor; Chromatography, Liquid; Disease Progression; Female; Humans; Inflammation; Kaplan-Meier Estimate; Male; Phenotype; Prognosis; Proteome; Proteomics; RNA, Messenger; Tandem Mass Spectrometry; Urinary Bladder Neoplasms
Επίσημο URL (Εκδότης):
DOI:
10.1002/ijc.32556
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.